Verified peer comparison
Sagimet Biosciences Inc. - Series A Common Stock vs Relmada Therapeutics, Inc. Financial Comparison
Sagimet Biosciences Inc. - Series A Common Stock versus Relmada Therapeutics, I…
Direct answer
Sagimet Biosciences Inc. - Series A Common Stock and Relmada Therapeutics, Inc. are compared on the same basis.
The comparison uses 2025 results reported in USD.
Common metrics include Revenue, Operating income, Net income, Operating cash flow.
Alpha Vantage
Get free Sagimet Biosciences Inc. - Series A Common Stock email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Sagimet Biosciences Inc. - Series A Common Stock Revenue
- 0 USD
- Relmada Therapeutics, Inc. Revenue
- 0 USD
- Sagimet Biosciences Inc. - Series A Common Stock Operating income
- -56,889,000 USD
- Relmada Therapeutics, Inc. Operating income
- -59,100,200 USD